Financial Data and Key Metrics Changes - The company reported consolidated net sales of $956 million for Q1, representing a growth of 10.9% year-over-year and 10% on an organic basis [12][13] - Adjusted EPS for the quarter was $0.45, a 25% increase compared to the previous year [12] - Consolidated gross margin was 38.5%, impacted by approximately $8 million in net tariff-related costs [14][15] Business Line Data and Key Metrics Changes - In the North America contract segment, net sales were $534 million, up 12% year-over-year, while new orders decreased by 8% [15][16] - The international contract segment saw net sales of $168 million, a 14.4% increase, but new orders were down 6.5% [16][17] - The global retail segment reported net sales of $254 million, up 6.4% year-over-year, with new orders increasing by 1.7% [17][18] Market Data and Key Metrics Changes - Office leasing activity for Class A space remains robust, with Manhattan leasing activity in August exceeding the 10-year monthly average [7] - North America retail web traffic increased by 17% compared to last year, indicating strong consumer interest [9] Company Strategy and Development Direction - The company is focusing on accelerated product creation, consistent execution, and prudent cost management while investing for profitable growth [6] - Plans include opening 12 to 15 new stores in the U.S. for the fiscal year, aiming to double the store footprint over the next several years [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum in the contract business, driven by increased office leasing activity and improving market conditions [7] - The company anticipates that tariff-related impacts will be mitigated in the second half of the fiscal year, with pricing actions expected to offset costs [19][20] Other Important Information - The company has a strong liquidity position with $481 million available and a net debt to EBITDA ratio of 2.92 times [15] - Management highlighted the importance of their workforce, noting recognition as a top workplace for innovators [11] Q&A Session Summary Question: Normalization of growth in the Americas - Management confirmed that growth has averaged 3.3% over the trailing two-quarter basis, with volume being a key driver [25][28] Question: Impact of discounting on projects - Management stated that discounting has remained stable and has not increased [33] Question: Breakdown of retail margin pressures - New store expenses were identified as the primary factor impacting retail margins, with expectations of revenue growth from new stores in the future [34][35] Question: Industry consolidation and competitive outlook - Management views industry consolidation positively, seeing it as an opportunity for growth and differentiation [44] Question: Tariff impacts and mitigation efforts - Management indicated that the net tariff-related impact was $8 million in Q1, with expectations for reduced impact in Q2 as pricing actions take effect [50]

Financial Data and Key Metrics Changes - Total adjusted sales grew 13% year-over-year to $740 million, with organic sales growth at 17% when excluding landing gear sales from the previous year [10] - Adjusted EBITDA increased 18% to $86.7 million, with adjusted EBITDA margins rising to 11.7% from 11.3% [10] - Adjusted diluted EPS rose 27% to $1.08 from $0.85 in the same quarter last year [11] Business Line Data and Key Metrics Changes - Parts supply sales increased 27% to $318 million, with adjusted EBITDA for this segment rising 34% to $43.8 million and adjusted EBITDA margins increasing to 13.8% from 13.1% [11] - Repair and engineering sales decreased 1% to $215 million, but organic sales growth was 8% when excluding the impact of landing gear divestiture [12] - Integrated solutions sales grew 10% year-over-year to $185 million, with adjusted EBITDA of $14.2 million, a 5% increase [14] Market Data and Key Metrics Changes - Adjusted sales growth to government customers increased 21%, while adjusted organic sales to commercial customers rose 15% [10] - Total commercial sales accounted for 71% of total sales, with government sales making up the remaining 29% [10] Company Strategy and Development Direction - The company is focused on driving growth through market share capture and new business, improving margins through cost efficiency, and increasing intellectual property through software investments [6] - The acquisition of Aerostrat is expected to enhance software capabilities and expand the reach of the Trax software solution [9] - The company aims to continue strengthening its offerings with targeted acquisitions to accelerate its strategy [17] Management's Comments on Operating Environment and Future Outlook - Management expects sales growth of 7%-10% for Q2, with organic sales growth for the full fiscal year approaching 10% [16] - The company is encouraged by the additional assets coming to market, which is expected to drive growth in the USM business [31] - Management remains confident in securing volume over time through strong relationships with large airline customers [28] Other Important Information - The company invested over $50 million in inventory to support future growth, particularly in the parts supply segment [15] - Net debt leverage increased slightly from 2.72x to 2.82x due to organic and inorganic investments [14] Q&A Session Summary Question: What is behind the slight uptick in full-year expectations? - Management indicated that parts supply is leading the way with a strong quarter showing 27% organic growth [19] Question: Can you comment on the pipeline for new distribution agreements? - Management noted that the majority of recent wins have been from taking market share, with a different exclusive distribution model resonating well [20][21] Question: Do you still expect to outgrow the market within distribution? - Management confirmed the outlook for distribution remains strong, expecting to continue growing above market rates [25] Question: Can you discuss cross-selling opportunities within repair and engineering? - Management stated they are in the early stages of executing their cross-selling strategy, with a long pipeline of opportunities [26][28] Question: Has the trend in USM sales continued into the current quarter? - Management confirmed a meaningful growth in USM business, driven by a loosening supply of assets [31] Question: What is the margin opportunity for parts supply if more USM comes available? - Management indicated that while USM margins have been depressed, they expect margins to expand as more supply comes to market [32] Question: Is there an agreement with Aerostrat employees to ensure retention? - Management confirmed an earnout agreement for key team members to incentivize their retention [33] Question: What is the company's exposure to engine-related aftermarket services? - Management highlighted significant exposure to the engine market, with 80% of USM parts business being engine-related [42] Question: How far along is Trax in becoming a digital marketplace? - Management stated that investments are being made to leverage Trax's position for offering parts and repair solutions, with announcements expected in the first half of 2026 [44]

Financial Data and Key Metrics Changes - The company reported consolidated net sales of $956 million for Q1 2026, representing a growth of 10.9% year-over-year and 10% on an organic basis [13] - Adjusted earnings per share (EPS) increased by 25% to $0.45, significantly outperforming guidance [13] - Consolidated gross margin for the quarter was 38.5%, impacted by approximately $8 million in net tariff-related costs [14] Business Line Data and Key Metrics Changes - In the North America contract segment, net sales were $534 million, up 12% year-over-year, while new orders decreased by 8% [16] - The international contract segment saw net sales improve to $168 million, a 14.4% increase, but new orders were down 6.5% [18] - The global retail segment reported net sales of $254 million, up 6.4% year-over-year, with new orders improving by 1.7% [19] Market Data and Key Metrics Changes - Office leasing activity for Class A space remains robust, with Manhattan leasing activity in August exceeding the 10-year monthly average [8] - North America retail web traffic increased by 17% year-over-year, indicating strong consumer interest [10] Company Strategy and Development Direction - The company is focusing on accelerated product creation, consistent execution, and prudent cost management while investing for profitable growth [6] - Plans include opening 12 to 15 new stores in the U.S. for the fiscal year, aiming to double the store footprint over the next several years [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum in the contract business, driven by increased office leasing activity and improving market conditions [8] - The company anticipates that pricing actions will offset tariff impacts in the second half of the fiscal year [14][20] Other Important Information - The company has undergone leadership changes, with Jeff Stutz promoted to Chief Operating Officer and Kevin Veltman serving as Interim Chief Financial Officer [4][5] - The company was recognized as a great workplace for innovators, reflecting its commitment to employee engagement [12] Q&A Session Summary Question: Normalization of growth in the Americas - Management confirmed that North America contract growth averaged 3.3% over the last two quarters, with volume being a key driver [27][29] Question: Impact of discounting on pricing - Management indicated that discounting has remained stable and has not increased [32] Question: Breakdown of retail margin pressures - New store expenses were identified as the primary factor impacting retail margins, with expectations of revenue growth from new stores in the future [34][35] Question: Industry consolidation and competitive outlook - Management views industry consolidation positively, seeing it as an opportunity for growth and differentiation [42] Question: Tariff impacts and mitigation efforts - Management clarified that the $8 million net tariff-related impact in Q1 is expected to decrease in Q2, with pricing actions in place to mitigate future costs [48][49]

Financial Data and Key Metrics Changes - Total adjusted sales grew 13% to $740 million year over year, with organic sales growth at 17% when excluding landing gear sales from the previous year [8] - Adjusted EBITDA increased 18% to $86.7 million, with adjusted EBITDA margins rising to 11.7% from 11.3% [8] - Adjusted diluted EPS increased by 27% to $1.08 from $0.85 in the same quarter last year [9] Business Line Data and Key Metrics Changes - Parts supply sales grew 27% to $318 million, with adjusted EBITDA for this segment increasing by 34% [9] - Repair and engineering sales decreased 1% to $215 million, but organic sales growth was 8% when excluding the impact of landing gear divestiture [10] - Integrated solutions sales increased by 10% year over year to $185 million, with adjusted operating income rising by 5% [11] Market Data and Key Metrics Changes - Adjusted sales growth to government customers increased 21%, while adjusted organic sales to commercial customers increased 15% [8] - Total commercial sales accounted for 71% of total sales, with government sales making up the remaining 29% [8] Company Strategy and Development Direction - The company is focused on driving growth through market share capture and new business, improving margins through cost efficiency, and increasing intellectual property through software investments [5] - The acquisition of Aerostrat is expected to enhance software capabilities and expand the reach of the Trax software solution [7] - The company aims to continue strengthening its offerings with targeted acquisitions to accelerate its strategy [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic sales growth approaching 10% for the full fiscal year, up from the previously cited 9% [14] - The company noted a strong start to the year and highlighted the strength of its business in the growing aviation aftermarket [14] - Management indicated that the supply of used serviceable materials (USM) is improving, which is expected to positively impact margins in the future [25][26] Other Important Information - The company invested over $50 million in inventory to support future growth, particularly in the parts supply segment [12] - The net debt leverage increased slightly from 2.72 times to 2.82 times due to organic and inorganic investments made during the quarter [11] Q&A Session Questions and Answers Question: What is behind the slight uptick in full-year expectations? - Management indicated that parts supply is leading the way with a strong quarter showing 27% organic growth [17] Question: Can you comment on the pipeline for new distribution agreements? - The majority of recent wins have been from taking market share, with a different exclusive distribution model resonating well with OEMs [18] Question: Do you still expect to outgrow the market within distribution? - Management maintained the outlook for distribution, expecting to continue growing above market rates [20] Question: What are the cross-selling opportunities within repair and engineering? - Management stated they are in the early stages of executing their cross-selling strategy, with a long pipeline of opportunities [22] Question: Has the trend in USM sales continued into the current quarter? - Management confirmed a meaningful growth in USM business, driven by a loosening supply of assets [25] Question: What is the margin opportunity for parts supply if more USM comes available? - Management expects margins to expand as more supply comes onto the market, although current margins in USM are tighter than historically [26] Question: Is there an agreement with Aerostrat employees to ensure retention? - There is a three-year earnout associated with the transaction to incentivize key team members to stay [28] Question: What is the company's exposure to engine-related aftermarket services? - Management confirmed significant exposure, with 80% of USM parts business related to engines [34] Question: How far along is Trax in becoming a digital marketplace? - Management indicated that investments are being made to leverage Trax's position for offering parts and repair solutions [36]

Financial Data and Key Metrics Changes - For fiscal year 2025, net revenue was $66.4 million, a slight increase from $65.2 million in the previous year [28] - Adjusted EBITDA for the year was $9.2 million, marking the third consecutive year of positive adjusted EBITDA, down from $10.8 million in the prior year [34][33] - Gross margin decreased to 69% from 75% in the previous year, primarily due to increased cost of sales in ADHD inventory [29][30] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $57.6 million, slightly down from $57.8 million, attributed to a decrease in the number of prescriptions written [28] - Pediatric portfolio revenue increased to $8.8 million from $7.3 million, reflecting a successful return-to-growth plan [29] Market Data and Key Metrics Changes - The U.S. market for major depressive disorder (MDD) is over $22 billion, with Exua targeting a significant portion of this market [7][9] - SSRIs and SNRIs represent over 60% of all antidepressants prescribed, indicating a competitive landscape for Exua [9][10] Company Strategy and Development Direction - The company is focusing on the launch of Exua, a novel treatment for MDD, which is expected to transform its business model [4][7] - Aytu BioPharma plans to leverage its psychiatry-focused sales force and proprietary patient access platform to drive product acquisitions aligned with its focus [6][19] - The company aims to minimize coverage barriers and enhance patient access through strategic payer contracting [17][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming launch of Exua, highlighting positive feedback from psychiatrists regarding the product [41][43] - The company anticipates that the Exua launch will position it as one of the fastest-growing CNS-focused companies in the industry [44] Other Important Information - The company has launched an authorized generic of Adzenys to maintain market share amid potential competition from Teva [21] - Aytu BioPharma has successfully raised $16.6 million through a public offering to support the Exua launch [35] Q&A Session Summary Question: Will there be a national sales meeting for Exua? - Management confirmed that a sales meeting is planned before the full launch in the first calendar quarter of 2026 [47] Question: Will promotional materials be pre-cleared? - Management stated they do not plan to pre-clear promotional materials but will follow the traditional submission process [48] Question: What is the strategy for engaging with payers? - Management indicated a selective approach to payer engagement, focusing on ensuring favorable contracting without undermining margins [50][52] Question: What are the expectations for ADHD and pediatric portfolio contributions? - Management expects the ADHD and pediatric portfolios to cover general and administrative expenses, with a break-even target of approximately $13 million quarterly [60][62] Question: What is the medical affairs strategy for Exua? - Management outlined plans for extensive medical affairs efforts, including presentations at medical conferences and educational programs [63]

Financial Data and Key Metrics Changes - Micron achieved record revenue of $37.4 billion in fiscal 2025, a nearly 50% increase year-over-year, with gross margins expanding by 17 percentage points to 41% [4][19] - Fiscal Q4 revenue was $11.3 billion, up 22% sequentially and 46% year-over-year, with DRAM revenue reaching a record $9 billion, up 69% year-over-year [19][20] - EPS for fiscal 2025 reached $8.29, reflecting a 538% increase compared to the prior year [19] Business Line Data and Key Metrics Changes - The combined revenue from HBM, high-capacity DIMMs, and LP server DRAM reached $10 billion, more than a five-fold increase compared to the prior fiscal year [5] - Cloud Memory Business Unit revenue was $4.5 billion, representing 40% of total company revenue, with gross margins of 59% [21] - Mobile Client Business Unit revenue was $3.8 billion, representing 33% of total company revenue, with gross margins of 36% [22] Market Data and Key Metrics Changes - Data center business accounted for a record 56% of total company revenue, with gross margins of 52% [10] - The calendar 2025 total server units are expected to grow approximately 10%, up from prior expectations of mid-single-digit growth [9] - Smartphone unit shipment expectations remain unchanged at low single-digit percentage range in calendar 2025, with an increasing mix of AI-ready smartphones [15] Company Strategy and Development Direction - Micron is positioned to benefit significantly from AI-driven demand, with a focus on advanced technologies like HBM and 1-gamma DRAM [5][6] - The company plans to continue investing in its Japan production capability and is making progress on its Singapore HBM assembly and test facility [9][8] - Micron aims to leverage its leadership in advanced technologies to maximize ROI and enhance product mix and profitability [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong demand for DRAM and NAND, driven by data center growth and AI applications [10][50] - The company anticipates further DRAM supply tightness in the industry and continued strengthening in NAND market conditions [18] - Management expects fiscal Q1 revenue to be a record $12.5 billion, with gross margins projected at 51.5% [27] Other Important Information - Micron invested $13.8 billion in CapEx in fiscal 2025, with expectations for higher CapEx in fiscal 2026 [18] - The company received a CHIPS Act grant disbursement for its new high-volume manufacturing fab in Idaho, with the first wafer output expected in the second half of calendar 2027 [8] - Micron's inventory levels improved, with ending inventory for fiscal Q4 at $8.4 billion, down $372 million sequentially [24][25] Q&A Session Summary Question: Guidance on revenue split between DRAM and NAND - Micron expects a heavier DRAM mix than NAND in the first quarter, with a projected sequential gross margin increase of 580 basis points [31] Question: Update on HBM total addressable market (TAM) - Micron anticipates the HBM TAM to reach $100 billion by 2030, with HBM bit CAGR expected to outgrow overall DRAM CAGR [34] Question: Transition from HBM3E to HBM4 - HBM4 production is expected to ramp in line with customer demand, with first shipments anticipated in the second quarter of 2026 [40] Question: Gross margin outlook - Micron expects gross margins to improve sequentially, driven by tight DRAM supply and improving NAND business [42] Question: DRAM inventory levels and customer orders - Micron expects DRAM inventories to remain tight, with healthy customer inventory levels and increased lead times for orders [58]

Financial Data and Key Metrics Changes - Micron Technology achieved record revenue of $37.4 billion in fiscal 2025, a nearly 50% increase year-over-year, with gross margins expanding by 17 percentage points to 41% [4][22] - Fiscal Q4 revenue was $11.3 billion, up 22% sequentially and 46% year-over-year, marking a quarterly record [22] - Earnings per share (EPS) reached $8.29, reflecting a 538% increase compared to the prior year [22] Business Line Data and Key Metrics Changes - DRAM revenue in fiscal Q4 was a record $9 billion, up 69% year-over-year, representing 79% of total revenue [22] - NAND revenue for fiscal Q4 was $2.3 billion, down 5% year-over-year but up 5% sequentially [23] - The Cloud Memory Business Unit (CMBU) generated $4.5 billion, accounting for 40% of total revenue, with gross margins of 59% [24] Market Data and Key Metrics Changes - Data center business reached a record 56% of total company revenue in fiscal 2025, with gross margins of 52% [11] - The total server units in the data center market are expected to grow approximately 10% in calendar 2025, up from previous expectations of mid-single-digit growth [10] - Smartphone unit shipment expectations remain unchanged at low single-digit percentage growth in calendar 2025, with an increasing mix of AI-ready smartphones [17] Company Strategy and Development Direction - Micron is positioned to benefit significantly from AI-driven demand, with a focus on advanced technologies such as HBM, 1-gamma DRAM, and G9 NAND [5][10] - The company plans to continue investing in its production capabilities in Japan and Singapore to meet future memory technology requirements [9][10] - Micron aims to leverage its leadership in advanced technologies to maximize ROI and enhance its product portfolio [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for DRAM and NAND products, driven by AI applications and traditional server growth [35][54] - The company anticipates continued tightness in the DRAM supply environment into calendar 2026, contributing to favorable pricing conditions [20][21] - Management highlighted the importance of AI in driving productivity and competitive positioning, with expectations of significant investments in memory related to AI [7][31] Other Important Information - Micron invested $13.8 billion in capital expenditures in fiscal 2025, with expectations for higher spending in fiscal 2026 [21] - The company received a CHIPS Act grant disbursement for its new manufacturing fab in Idaho, with the first wafer output expected in the second half of calendar 2027 [9] - Micron's 1-gamma DRAM node achieved mature yields 50% faster than the previous generation, demonstrating its technological leadership [8] Q&A Session Summary Question: Guidance on revenue split between DRAM and NAND - Micron expects a heavier DRAM mix in the first quarter, with a projected sequential gross margin increase of 580 basis points driven by pricing and strong execution [34][36] Question: Update on HBM total addressable market (TAM) - Management reiterated the expectation for HBM TAM to reach $100 billion by 2030, with HBM bit CAGR expected to outpace overall DRAM CAGR [38][39] Question: Transition from HBM3E to HBM4 - HBM4 production is set to ramp in line with customer demand, with expectations for increased market share in 2026 [44][45] Question: Gross margin outlook - Management anticipates sequential gross margin improvement in the first half of fiscal 2026, supported by tight DRAM supply and favorable pricing [46][48] Question: DRAM demand sustainability - Strong demand for AI applications is broadening the demand vector for DRAM across various markets, including data centers and smartphones [53][54] Question: CapEx breakdown for fiscal 2026 - Micron's fiscal 2026 CapEx will primarily focus on DRAM, with ongoing investments in construction and facilities [57][59]

Financial Data and Key Metrics Changes - Micron achieved record revenue of $37.4 billion in fiscal 2025, a nearly 50% increase year-over-year, with gross margins expanding by 17 percentage points to 41% [4][21] - Fiscal Q4 revenue was $11.3 billion, up 22% sequentially and 46% year-over-year, marking a quarterly record [21] - EPS reached $8.29, reflecting a 538% increase compared to the prior year [21] Business Line Data and Key Metrics Changes - DRAM revenue in fiscal Q4 was a record $9 billion, up 69% year-over-year, representing 79% of total revenue [21][22] - NAND revenue for fiscal Q4 was $2.3 billion, down 5% year-over-year but up 5% sequentially [22] - The Cloud Memory Business Unit generated $4.5 billion in revenue, representing 40% of total company revenue, with gross margins of 59% [23] Market Data and Key Metrics Changes - Data center business accounted for a record 56% of total company revenue in fiscal 2025, with gross margins of 52% [11] - The outlook for total server units in calendar 2025 is expected to grow approximately 10%, up from previous mid-single-digit growth expectations [10] - Smartphone unit shipment expectations remain unchanged at low single-digit percentage growth in calendar 2025 [16] Company Strategy and Development Direction - Micron is positioned to benefit significantly from AI-driven demand, with a focus on advanced technologies like HBM and 1-gamma DRAM [5][10] - The company plans to continue investing in its Japan production capability and has begun design work for a second manufacturing fab in Idaho [9][10] - Micron aims to leverage its leadership in advanced technologies to maximize ROI and enhance product mix and profitability [5][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong demand across various end markets, including data centers, PCs, and automotive, driven by AI trends [11][53] - The company anticipates continued tightness in DRAM supply and improving conditions in the NAND market [18][20] - Management expects fiscal Q1 revenue to be a record $12.5 billion, with gross margins projected at 51.5% [29] Other Important Information - Micron invested $13.8 billion in CapEx in fiscal 2025, with expectations for higher spending in fiscal 2026 [20] - The company received a CHIPS grant disbursement for its new manufacturing fab in Idaho, with the first wafer output expected in the second half of calendar 2027 [9] Q&A Session Summary Question: Guidance on revenue split between DRAM and NAND - Management indicated that the first quarter will have a heavier DRAM mix than NAND, with expectations for a 580 basis points sequential margin expansion driven by pricing and strong execution [33][34] Question: Update on HBM total addressable market (TAM) - Management reiterated that the HBM TAM is expected to reach $100 billion by 2030, with HBM bit CAGR outpacing DRAM CAGR [36][37] Question: Transition from HBM3 to HBM4 - HBM4 production is expected to ramp in line with customer demand, with first shipments anticipated in the second quarter of 2026 [42][43] Question: Sustainability of DRAM demand - Management noted strong demand across AI applications, traditional servers, and smartphones, contributing to a healthy demand-supply environment [52][53] Question: CapEx breakdown for fiscal 2026 - Management stated that the majority of CapEx in 2026 will be for DRAM, with ongoing construction and equipment investments [56][57]

Financial Data and Key Metrics Changes - For fiscal year 2025, net revenue was $66.4 million, a slight increase from $65.2 million in the previous year [27] - Adjusted EBITDA for the year was $9.2 million, marking the third consecutive year of positive adjusted EBITDA, compared to $10.8 million in the prior year [32] - Gross margin decreased to 69% from 75% in the previous year, primarily due to increased cost of sales in ADHD inventory [28][29] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $57.6 million, down from $57.8 million, attributed to a decrease in the number of prescriptions written [27] - Pediatric portfolio revenue increased to $8.8 million from $7.3 million, reflecting a successful return-to-growth plan [28] Market Data and Key Metrics Changes - The U.S. market for major depressive disorder (MDD) is over $22 billion, with Exua targeting a significant portion of this market [7][9] - SSRIs and SNRIs represent over 60% of all antidepressants prescribed, indicating a competitive landscape for Exua [9][10] Company Strategy and Development Direction - The company is focusing on the launch of Exua, a novel treatment for MDD, which is expected to transform its business model [4][7] - Aytu BioPharma plans to leverage its psychiatry-focused sales force and proprietary Aytu RxConnect platform for the launch of Exua [6][14] - The company aims to maintain market share in the ADHD segment despite the entry of generics by launching an authorized generic of Adzenys [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming launch of Exua and its potential to address unmet needs in the MDD market [4][11] - The company anticipates a positive trajectory for Exua as it ramps up commercial efforts, expecting to exit fiscal 2026 as one of the fastest-growing CNS-focused companies [42] Other Important Information - The company has successfully raised $16.6 million through a public offering to support the Exua launch [34] - Aytu BioPharma has restructured its operations, resulting in a new cost structure that projects a break-even level of approximately $52.6 million annually [30] Q&A Session Summary Question: Will there be a national sales meeting for Exua? - Management confirmed that a sales meeting is planned before the full launch in the first calendar quarter of 2026 [45] Question: Will promotional materials be pre-cleared? - Management stated they do not plan to pre-clear promotional materials but will follow the traditional submission process [46] Question: What is the strategy for engaging with payers? - Management indicated a selective approach to payer engagement, focusing on government payers due to favorable coverage for MDD [50][52] Question: What are the expectations for the ADHD and pediatric franchises? - Management expects the ADHD and pediatric portfolios to cover general and administrative expenses, with a focus on maintaining margin positivity [58][60] Question: What is the plan for medical affairs and education for Exua? - Management outlined extensive efforts in medical affairs, including engagement with key opinion leaders and participation in medical conferences [61]

Financial Data and Key Metrics Changes - For fiscal year 2025, net revenue was $66.4 million, a slight increase from $65.2 million in the previous year [28] - Adjusted EBITDA for the year was $9.2 million, marking the third consecutive year of positive adjusted EBITDA [34] - The net loss for the year was $13.6 million, an improvement from a net loss of $15.8 million in the prior year [32] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $57.6 million, down from $57.8 million, attributed to a decrease in the number of prescriptions written [28] - Pediatric portfolio revenue increased to $8.8 million from $7.3 million, reflecting a successful return-to-growth plan [29] - Gross margin decreased to 69% from 75%, primarily due to increased cost of sales in ADHD inventory [29] Market Data and Key Metrics Changes - The U.S. market for major depressive disorder (MDD) is over $22 billion, with more than 340 million prescriptions written annually [9] - SSRIs and SNRIs account for approximately 220 million TRXs, representing over 60% of all antidepressants prescribed [9] Company Strategy and Development Direction - The company is focusing on the upcoming launch of Exua, a novel treatment for MDD, which is expected to transform its business [4][7] - Aytu BioPharma plans to leverage its psychiatry-focused sales force and proprietary Aytu RxConnect patient access platform for product acquisitions aligned with its focus [6] - The company aims to minimize coverage barriers and enhance patient access through selective payer contracting [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the Exua launch, highlighting positive feedback from psychiatrists regarding the product's potential [41][43] - The company anticipates that the Exua opportunity will significantly enhance its growth trajectory, positioning it as a leading CNS-focused company [44] Other Important Information - The company has successfully completed a public offering totaling $16.6 million gross, which is seen as validation of the Exua opportunity [35] - Aytu BioPharma has launched an authorized generic of Adzenys to maintain market share amid potential competition from Teva [21] Q&A Session Summary Question: Will there be a national sales meeting for Exua? - Management confirmed that a sales meeting is expected before the full launch in the first calendar quarter of 2026 [47] Question: Will promotional materials be pre-cleared? - Management stated they do not plan to pre-clear promotional materials, citing confidence in their compliant promotional platform [48] Question: What is the plan for engaging with payers? - Management indicated a selective approach to payer engagement, focusing on ensuring favorable contracting without undermining margins [52][54] Question: What are the expectations for the ADHD and pediatric franchises? - Management expects the ADHD and pediatric portfolios to cover general and administrative expenses, with a focus on maintaining margin positivity [60][62] Question: What is the medical affairs strategy for Exua? - Management outlined an extensive medical affairs effort, including engagement with key opinion leaders and participation in medical conferences [63]